Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Net Income Loss of -$10.31 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +11.3% in Net Income Loss from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2004 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 22 years of available data (2004 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Net Income Loss has declined by 14,019.2%.
- Historical annual values: Fiscal year 2025: -$10.31 million | Fiscal year 2024: -$11.62 million | Fiscal year 2023: -$17.19 million | Fiscal year 2022: -$24.28 million | Fiscal year 2021: -$24.46 million | Fiscal year 2020: -$31.81 million | Fiscal year 2019: -$23.25 million | Fiscal year 2018: -$13.95 million | Fiscal year 2017: -$4.95 million | Fiscal year 2016: -$4.98 million | Fiscal year 2015: -$8.49 million | Fiscal year 2014: -$9.25 million | Fiscal year 2013: -$4.90 million | Fiscal year 2012: -$3.43 million | Fiscal year 2011: -$3.92 million | Fiscal year 2010: -$2.42 million | Fiscal year 2009: -$1.78 million | Fiscal year 2008: -$3.47 million | Fiscal year 2007: -$6.24 million | Fiscal year 2006: -$3.32 million | Fiscal year 2005: -$18.84 million | Fiscal year 2004: -$73.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: